Publications by authors named "Mark G Anderson"

Claim this Profile
F
From fragmentation to resilience: Connectivity and habitat diversity as drivers of fish persistence in California watersheds.
Jeanette K Howard, Analie R Barnett, Kurt A Fesenmyer, Mark G Anderson

PLoS One· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS.
Robert K Suter, Anna M Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Mark G Anderson

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agreeing that maps can disagree: Moving away from map confusion in conservation.
Lindsay M Dreiss, Mark G Anderson, Brooke L Bateman, R Travis Belote, Julia L Michalak

Bioscience· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A resilient and connected network of sites to sustain biodiversity under a changing climate.
Mark G Anderson, Melissa Clark, Arlene P Olivero, Analie R Barnett, Kimberly R Hall

Proc Natl Acad Sci U S A· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Mark G Anderson

Neurooncol Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Mark G Anderson, Qian Zhang, Luis E Rodriguez, Claudie M Hecquet, Cherrie K Donawho

BMC Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Mark G Anderson, Hugh D Falls, Michael J Mitten, Anatol Oleksijew, Kedar S Vaidya

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opinion: To advance sustainable stewardship, we must document not only biodiversity but geodiversity.
Franziska Schrodt, Joseph J Bailey, W Daniel Kissling, Kenneth F Rijsdijk, Arie C Seijmonsbergen, Mark G Anderson

Proc Natl Acad Sci U S A· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A stream classification system to explore the physical habitat diversity and anthropogenic impacts in riverscapes of the eastern United States.
Ryan A McManamay, Matthew J Troia, Christopher R DeRolph, Arlene Olivero Sheldon, Analie R Barnett, Mark G Anderson

PLoS One· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.
Kedar S Vaidya, Anatol Oleksijew, Lora A Tucker, William N Pappano, Mark G Anderson

Pharmacology· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Future of Landscape Conservation.
Robert F Baldwin, Stephen C Trombulak, Paul B Leonard, Reed F Noss, Jodi A Hilty, Mark G Anderson

Bioscience· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both -Amplified and c-Met-Overexpressing Tumors, Irrespective of Pathway Dependence.
Jieyi Wang, Mark G Anderson, Anatol Oleksijew, Kedar S Vaidya, Erwin R Boghaert

Clin Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The theory behind, and the challenges of, conserving nature's stage in a time of rapid change.
Joshua J Lawler, David D Ackerly, Christine M Albano, Mark G Anderson, Solomon Z Dobrowski, Eric W Sanderson

Conserv Biol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying circuit theory for corridor expansion and management at regional scales: tiling, pinch points, and omnidirectional connectivity.
David Pelletier, Melissa Clark, Mark G Anderson, Bronwyn Rayfield, Michael A Wulder

PLoS One· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating climate resilience for conservation across geophysical settings.
Mark G Anderson, Melissa Clark, Arlene Olivero Sheldon

Conserv Biol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization.
O Jameel Shah, Xiaoyu Lin, Leiming Li, Xiaoli Huang, Junling Li, Mark G Anderson

Proc Natl Acad Sci U S A· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conserving the stage: climate change and the geophysical underpinnings of species diversity.
Mark G Anderson, Charles E Ferree

PLoS One· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
Stephen K Tahir, John Wass, Mary K Joseph, Viswanath Devanarayan, Paul Hessler, Mark G Anderson

Mol Cancer Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of methods for use of formalin-fixed, paraffin-embedded tissue samples in RNA expression profiling.
Lisa Roberts, Jessica Bowers, Kelly Sensinger, Andrew Lisowski, Robert Getts, Mark G Anderson

Genomics· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Christin Tse, Alexander R Shoemaker, Jessica Adickes, Mark G Anderson, Jun Chen

Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.
Edward T Olejniczak, Charles Van Sant, Mark G Anderson, Gang Wang, Stephen K Tahir

Mol Cancer Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Stephen K Tahir, Xiufen Yang, Mark G Anderson, Susan E Morgan-Lappe, Aparna V Sarthy

Cancer Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway.
Charles Van Sant, Gang Wang, Mark G Anderson, Oscar J Trask, Rick Lesniewski

Mol Cancer Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.
Aparna V Sarthy, Susan E Morgan-Lappe, Dorothy Zakula, Lawrence Vernetti, Mark Schurdak, Mark G Anderson

Mol Cancer Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.
Wen-Zhen Gu, Ingrid Joseph, Yi-Chun Wang, David Frost, Gerard M Sullivan, Mark G Anderson

Anticancer Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis